Lp(a): The Genetic Risk Factor Most Doctors Never Test
Lp(a): The Genetic Risk Factor Most Doctors Never Test
You could have a normal LDL, a normal total cholesterol, a clean stress test, and still carry a cardiovascular risk factor that doubles or triples your chance of a heart attack. It’s called Lp(a) — lipoprotein(a) — and roughly 20% of the global population has elevated levels.
Your doctor has almost certainly never tested it. Most don’t. A standard lipid panel shows LDL-C, HDL-C, and triglycerides. It does not include Lp(a). One in five people walks around with a genetic risk factor that never appears on any lab report, never triggers a conversation, and never informs treatment decisions.
What it is, why it matters, and what you can actually do about it.
What Lp(a) Is — And What It Isn’t
Lp(a) is a lipoprotein particle — similar to LDL in structure, but with an extra protein called apolipoprotein(a) attached to it. This protein makes Lp(a) particles stickier and more prone to embedding in artery walls. It also gives Lp(a) prothrombotic properties: it interferes with the body’s clot-dissolving mechanisms, meaning it both builds plaque and makes the clots that form on plaque more dangerous.
Think of LDL and Lp(a) as two different vehicles carrying cholesterol into your artery walls. A standard lipid panel counts the cargo (cholesterol). It doesn’t distinguish which vehicles are doing the delivering. You can have “normal” LDL cholesterol and still have high cardiovascular risk — the Lp(a) vehicles are doing damage that never shows up on the standard panel.
What Lp(a) is NOT:
- Not modifiable by lifestyle. Diet, exercise, and weight loss don’t meaningfully change Lp(a) levels. This is genetically determined.
- Not responsive to statins. Statins lower LDL and ApoB. They do not lower Lp(a). In some cases, statins modestly increase it.
- Not something that needs retesting. Because it’s genetically fixed, you test it once. The number you get at age 35 will be the same number at age 65.
Why Your Doctor Probably Hasn’t Tested It
The Lp(a) test costs $30-50 at most labs. It requires no special preparation. It’s a single blood draw, often from the same tube as your lipid panel. So why doesn’t it show up on standard screening?
Two reasons. First, there’s no FDA-approved drug that specifically lowers Lp(a) (as of 2026). That creates a perception problem: if you can’t directly treat it, why test it? This logic falls apart quickly. Knowing your Lp(a) changes how aggressively you manage everything else. It changes your ApoB target. It changes whether you start medication sooner versus later. It changes your entire cardiovascular risk picture.
Second, most primary care screening algorithms are designed around population-level thresholds for common conditions. Lp(a) is a genetically variable risk factor that affects about 1 in 5 people but not the majority. Population-level screening tools are built for majority patterns. Individual risk assessment requires looking at the full picture, including the tests that standard screening skips.
What Lp(a) Numbers Mean
Lp(a) is measured in nmol/L (nanomoles per liter) or mg/dL. The nmol/L measurement is preferred because it directly counts particle number, while mg/dL measures mass and can be less accurate. The two units are not directly convertible — don’t try to multiply by a fixed factor.
How Protocol stratifies Lp(a) in our Cardiovascular Risk protocol:
| Lp(a) Level | Risk Category | What It Means |
|---|---|---|
| Below 50 nmol/L | Normal | Does not meaningfully add to cardiovascular risk. No specific action needed. No retesting needed. |
| 50-74 nmol/L | Modestly elevated | Contributes to risk tier assignment. No specific Lp(a) therapy available. Managed through more aggressive ApoB targets. |
| 75-125 nmol/L | High | Classified as Tier B (High Risk) in Protocol’s system. ApoB target drops to below 60 mg/dL. All other modifiable risk factors managed aggressively. |
| Above 125 nmol/L | Very High | Classified as Tier A (Very High Risk). ApoB target drops to below 55 mg/dL. Immediate pharmacotherapy for ApoB. Zero tolerance for suboptimal management of any modifiable risk factor. |
Two things about these numbers. First, Lp(a) risk is additive — it stacks on top of whatever risk your ApoB, blood pressure, blood sugar, and other factors already create. An Lp(a) of 150 nmol/L in someone with an ApoB of 60 looks very different from the same Lp(a) in someone with an ApoB of 130. Both need attention, but the second person is accumulating risk from multiple directions at once.
Second, Lp(a) risk is independent. It doesn’t go away when you fix other numbers. Lowering your ApoB from 130 to 70 is excellent and necessary, but it doesn’t erase the Lp(a)-driven risk. It reduces your total risk by addressing what’s modifiable.
The “Normal LDL” Trap
This is where Lp(a) does the most damage — not because the molecule itself is more destructive, but because the false reassurance of a “normal” lipid panel leads to years of inaction.
A scenario that plays out all the time: A 45-year-old gets an annual physical. LDL-C comes back at 110 mg/dL. Doctor says, “Your cholesterol looks good.” Patient assumes they’re fine. Fifteen years later, they have a heart attack.
What the standard lipid panel missed: Lp(a) was 180 nmol/L. That Lp(a), combined with a not-actually-optimal LDL and 15 years of cumulative exposure, built enough plaque to cause an event. If Lp(a) had been tested at 45, the ApoB target would have been set below 55 mg/dL, pharmacotherapy would have started immediately, and 15 years of aggressive risk management would have cut that outcome probability down hard.
This isn’t hypothetical. Studies estimate that elevated Lp(a) contributes to approximately 10% of cardiovascular events globally. Those events disproportionately occur in people whose conventional risk markers looked reassuring.
If you’ve been told your cholesterol is “fine” but you’ve never had an Lp(a) test, you have incomplete information. Related reading: What to Do When Your ApoB Is High and What Borderline Cholesterol Actually Means.
What You Can Actually Do About High Lp(a)
This part frustrates people, so let’s be direct: there is no approved therapy that specifically lowers Lp(a) as of 2026. Several drugs are in Phase 3 clinical trials — pelacarsen, olpasiran, and lepodisiran all target Lp(a) and have shown 80-90%+ reductions in trials — but none have received FDA approval yet. When they do, the treatment picture will change.
Until then, the management strategy is clear: lower everything else more aggressively.
Lower ApoB More Aggressively
This is the primary lever. If you can’t reduce the Lp(a) particles directly, you reduce every other atherogenic particle as much as possible. That means a lower ApoB target — below 60 mg/dL for Lp(a) 75-125, below 55 mg/dL for Lp(a) above 125. These targets are more aggressive than what most guidelines recommend for the general population, and they’re deliberately so.
In practice: someone with high Lp(a) is more likely to need pharmacotherapy (a statin, ezetimibe, or both) and more likely to need it sooner. Lifestyle interventions — Mediterranean diet, regular exercise, omega-3 supplementation — are still part of the plan, but they go alongside medication, not instead of it.
For the full picture on how ApoB and Lp(a) interact in Protocol’s risk model, read The ApoB-Lp(a) Connection: Why Both Numbers Matter.
Optimize Every Modifiable Risk Factor
When one major risk factor is genetically fixed, every modifiable factor matters more. Blood pressure at 135/85 instead of 120/75 matters more when Lp(a) is elevated. A fasting insulin of 14 instead of 6 matters more. Smoking, even occasional, matters more. Each additional risk factor compounds with the Lp(a)-driven risk.
Protocol’s approach to high Lp(a) members is explicit: zero tolerance for suboptimal management of any modifiable risk factor. ApoB at target, blood pressure optimized, insulin sensitivity verified, exercise prescription met, dietary protocol followed. No single change erases the genetic risk. But the accumulation of optimal management across every domain creates the best possible risk profile given the hand you were dealt.
PCSK9 Inhibitors — A Partial Answer
PCSK9 inhibitors (evolocumab and alirocumab) are primarily prescribed for aggressive ApoB/LDL lowering, but they also reduce Lp(a) by approximately 20-30%. They’re not prescribed specifically for Lp(a), but this secondary benefit gives them additional weight in the pharmacotherapy decision for members with high Lp(a) who need aggressive ApoB management. Protocol’s escalation algorithm accounts for this when making step 3 and step 4 treatment decisions.
Screen Your Family
Lp(a) is genetic. If yours is elevated, your first-degree relatives — parents, siblings, children — have a real chance of elevated Lp(a) as well. A single blood test can identify whether they carry the same risk factor. Protocol recommends cascade screening for all first-degree relatives of members with Lp(a) above 75 nmol/L.
One lab test can change the trajectory of someone’s cardiovascular risk management for the rest of their life. That’s rare.
What Happens When Lp(a)-Lowering Drugs Arrive
The trials underway are promising. Pelacarsen, olpasiran, and lepodisiran all use different mechanisms to reduce Lp(a) production, and Phase 2 data showed reductions of 80-98%. Phase 3 outcome trials are testing whether those reductions translate to fewer heart attacks and strokes — the endpoint that matters.
If these trials succeed and the drugs gain FDA approval, it will change the management of high Lp(a) in a major way. For the first time, the genetic risk factor itself becomes treatable, not just the surrounding factors. Protocol tracks these trials and will discuss newly approved options with affected members as they become available.
But that future doesn’t change the present. Right now, the actionable step is simple: get tested once. Know your number. If it’s elevated, manage aggressively. If it’s normal, move on and never think about it again.
How Protocol Tests Lp(a)
In Protocol’s Cardiovascular Risk protocol, Lp(a) is part of the baseline testing panel for every member. One test. One time. It costs $30-50 and it’s included in the initial lab draw alongside ApoB, a full lipid panel, and hsCRP.
When results come back, Lp(a) gets a dedicated discussion — not buried in a lab printout, not glossed over in a list of 20 values. If your Lp(a) is elevated, you leave that encounter understanding exactly what it means, how it changes your risk tier, what your specific ApoB target is, and what the management plan looks like.
You also leave knowing that this number is genetic, not your fault, not caused by anything you did or didn’t eat, and not something to panic about. It’s information. Specific, actionable information that changes how we manage your cardiovascular health.
A lot of our members discover elevated Lp(a) for the first time during their initial assessment — including members who’ve had “normal” annual physicals for decades. The test was always available. It just wasn’t ordered.
The One-Test Argument
If you take one thing from this article: ask your doctor to order an Lp(a) test, or order it yourself through a direct-to-consumer lab for $30-50. You only need to do it once in your life.
If the result is below 50 nmol/L, you have useful information: Lp(a) is not a factor in your cardiovascular risk. You never need to test it again.
If the result is elevated, you have even more useful information: a risk factor that was silently shaping your cardiovascular future is now visible, quantified, and manageable. Not by changing Lp(a) itself — that’s not yet possible — but by managing everything around it with the precision that the additional risk demands.
Twenty percent of people carry this risk factor. Most will never know. A single $30 test determines which group you’re in.
Ready to find out where you stand? Protocol’s Foundation Assessment measures what your annual physical misses — ApoB, HOMA-IR, DEXA body composition, VO2 max — and builds a specific action plan from the data.